Advertisement

Systemic Radiotherapy with Monoclonal Antibodies

Options and Problems

  • Marie-Luise Sautter-Bihl
  • Heiner Bihl
  • Michael Wannenmacher

Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 141)

Table of contents

  1. Front Matter
    Pages I-IX
  2. M. R. Zalutsky, J. M. Schuster, P. K. Garg, G. E. Archer Jr., M. W. Dewhirst, D. D. Bigner
    Pages 101-122
  3. J. F. Eary, O. W. Press
    Pages 177-182
  4. Back Matter
    Pages 193-197

About these proceedings

Introduction

Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio­ labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology.

Keywords

Antigen Antikörper Tumor brain cancer treatment carcinoma cell dosimetry hyperthermia immunotherapy lymphoma nuclear medicine radiation radiotherapy targeted therapy

Editors and affiliations

  • Marie-Luise Sautter-Bihl
    • 1
  • Heiner Bihl
    • 2
  • Michael Wannenmacher
    • 3
  1. 1.Klinik für StrahlentherapieStädt. Kliniken KarlsruheKarlsruheGermany
  2. 2.Klinik für NuklearmedizinKatharinenhospital StuttgartStuttgartGermany
  3. 3.Radiologische Klinik Abteilung für Klinische RadiologieHeidelbergGermany

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-79952-5
  • Copyright Information Springer-Verlag Berlin Heidelberg 1996
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-79954-9
  • Online ISBN 978-3-642-79952-5
  • Series Print ISSN 0080-0015
  • Buy this book on publisher's site
Industry Sectors
Pharma
Health & Hospitals
Biotechnology
Oncology & Hematology